Physician profile
Sami E Asmar
NPI 1861466500
$12,482.49
in general payments reported to CMS, 2019-2025
54 companies · $2,123 in 2025
The $2,123 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2020: $1,282 · 2021: $2,003 · 2022: $2,089 · 2023: $1,513 · 2024: $1,736 · 2025: $2,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,372.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,616.01 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $1,518.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,023.84 | 2019-2025 | |
| Abbvie INC. | $1,005.52 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $796.14 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $571.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $559.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $492.38 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $435.70 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $373.89 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $367.53 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $346.83 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $318.04 | 2020-2024 | Verquvo, Belsomra, Januvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.66 | 2020-2025 | Jardiance, Spevigo, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $285.70 | 2024-2025 | Rexulti |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.87 | 2019-2025 | Xifaxan, Relistor |
| Astellas Pharma US INC | $215.91 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $213.39 | 2019-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $198.69 | 2019-2021 | |
| Exact Sciences Corporation | $189.53 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $152.43 | 2021-2023 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $124.69 | 2019-2024 | Camzyos |
| United Therapeutics Corporation | $105.19 | 2022-2025 | Tyvaso |
| Nestle Healthcare Nutrition INC. | $86.98 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $70.31 | 2022-2023 | Seglentis |
| Phathom Pharmaceuticals, INC. | $64.72 | 2025 | Voquezna |
| Halozyme INC | $62.77 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.00 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $47.12 | 2021-2025 | Keveyis |
| Lundbeck LLC | $46.35 | 2024-2025 | Rexulti |
| Allergan, INC. | $43.71 | 2019-2020 | |
| Axsome Therapeutics, INC. | $43.51 | 2025 | Auvelity |
| Antares Pharma, INC. | $42.10 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Ferring Pharmaceuticals INC. | $39.77 | 2022-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $38.90 | 2024 | |
| Abbott Laboratories | $35.37 | 2021-2022 | |
| Tolmar, INC. | $34.85 | 2024-2025 | Jatenzo |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.92 | 2022 | |
| Radius Health, INC. | $25.95 | 2019 | |
| Medicomp INC | $24.73 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.57 | 2022 | |
| Daiichi Sankyo INC. | $21.20 | 2022 | |
| Acadia Pharmaceuticals INC | $19.36 | 2022 | |
| Alvogen INC | $19.01 | 2023 | Teriparatide |
| Paratek Pharmaceuticals, INC. | $18.01 | 2025 | Nuzyra |
| Ardelyx, INC. | $17.01 | 2024 | Ibsrela |
| Pulmonx Corporation | $16.73 | 2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Biohaven Pharmaceuticals, INC. | $15.70 | 2021 | |
| Insmed, INC. | $14.85 | 2025 | Arikayce |
| Shield Therapeutics INC | $13.07 | 2024 | |
| Jazz Pharmaceuticals INC. | $12.92 | 2021 | |
| Strongbridge US INC. | $11.87 | 2020 | |
| Almatica Pharma LLC | $11.82 | 2022 | |
| Si-Bone, INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Asmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.